Skip to main content

Boundless Bio to Participate at Two Upcoming Investor Conferences

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, today announced that its Chief Executive Officer, Zachary Hornby, will participate in a presentation and fireside chat at upcoming investor conferences:

Piper Sandler 34th Annual Healthcare Conference

Format: Presentation

Date: Tuesday, November 29, 2022

Time: 8:30 AM – 8:50 AM ET

5th Annual Evercore ISI HealthCONx Conference

Format: Fireside chat (virtual)

Date: Tuesday, November 29, 2022

Time: 1:50 PM – 2:10 PM ET

About Boundless Bio

Boundless Bio is a next-generation precision oncology company dedicated to the discovery and development of a new class of drugs targeting a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with oncogene amplified cancers.

For more information, visit www.boundlessbio.com.

Follow us on LinkedIn and Twitter.

Contacts

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  255.36
+5.45 (2.18%)
AAPL  273.17
+7.00 (2.63%)
AMD  303.46
+18.97 (6.67%)
BAC  53.12
-0.36 (-0.67%)
GOOG  337.73
+7.26 (2.20%)
META  674.72
+5.88 (0.88%)
MSFT  432.92
+8.76 (2.07%)
NVDA  202.50
+2.62 (1.31%)
ORCL  187.50
+6.33 (3.49%)
TSLA  387.51
+1.09 (0.28%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.